A citation-based method for searching scientific literature

Wenjing Zhou, Karin Jirström, Christine Johansson, Rose-Marie Amini, Carl Blomqvist, Olorunsola Agbaje, Fredrik Wärnberg. BMC Cancer 2010
Times Cited: 31







List of co-cited articles
187 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Karla Kerlikowske, Annette M Molinaro, Mona L Gauthier, Hal K Berman, Fred Waldman, James Bennington, Henry Sanchez, Cynthia Jimenez, Kim Stewart, Karen Chew,[...]. J Natl Cancer Inst 2010
234
45

Identification of a basal-like subtype of breast ductal carcinoma in situ.
Chad A Livasy, Charles M Perou, Gamze Karaca, David W Cowan, Diane Maia, Susan Jackson, Chiu-Kit Tse, Sarah Nyante, Robert C Millikan. Hum Pathol 2007
156
38


Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.
S E Clark, J Warwick, R Carpenter, R L Bowen, S W Duffy, J L Jones. Br J Cancer 2011
84
25

A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.
Lawrence J Solin, Robert Gray, Frederick L Baehner, Steven M Butler, Lorie L Hughes, Carl Yoshizawa, Diana B Cherbavaz, Steven Shak, David L Page, George W Sledge,[...]. J Natl Cancer Inst 2013
322
25

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.
E Rakovitch, S Nofech-Mozes, W Hanna, S Narod, D Thiruchelvam, R Saskin, J Spayne, C Taylor, L Paszat. Br J Cancer 2012
89
25

HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.
Robert E Roses, E Carter Paulson, Anupama Sharma, Jeanne E Schueller, Harvey Nisenbaum, Susan Weinstein, Kevin R Fox, Paul J Zhang, Brian J Czerniecki. Cancer Epidemiol Biomarkers Prev 2009
93
22



Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.
Torsten O Nielsen, Forrest D Hsu, Kristin Jensen, Maggie Cheang, Gamze Karaca, Zhiyuan Hu, Tina Hernandez-Boussard, Chad Livasy, Dave Cowan, Lynn Dressler,[...]. Clin Cancer Res 2004
22

Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
Aslaug Aamodt Muggerud, Michael Hallett, Hilde Johnsen, Kristine Kleivi, Wenjing Zhou, Simin Tahmasebpoor, Rose-Marie Amini, Johan Botling, Anne-Lise Børresen-Dale, Therese Sørlie,[...]. Mol Oncol 2010
81
22

Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
Nina Bijker, Philip Meijnen, Johannes L Peterse, Jan Bogaerts, Irène Van Hoorebeeck, Jean-Pierre Julien, Massimiliano Gennaro, Philippe Rouanet, Antoine Avril, Ian S Fentiman,[...]. J Clin Oncol 2006
437
22

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
Irene L Wapnir, James J Dignam, Bernard Fisher, Eleftherios P Mamounas, Stewart J Anderson, Thomas B Julian, Stephanie R Land, Richard G Margolese, Sandra M Swain, Joseph P Costantino,[...]. J Natl Cancer Inst 2011
449
22

Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast.
E Provenzano, J L Hopper, G G Giles, G Marr, D J Venter, J E Armes. Eur J Cancer 2003
89
19

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
19

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
19

Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution.
D Craig Allred, Yun Wu, Sufeng Mao, Iris D Nagtegaal, Sangjun Lee, Charles M Perou, Syed K Mohsin, Peter O'Connell, Anna Tsimelzon, Dan Medina. Clin Cancer Res 2008
203
19

Classification of ductal carcinoma in situ by gene expression profiling.
Juliane Hannemann, Arno Velds, Johannes B G Halfwerk, Bas Kreike, Johannes L Peterse, Marc J van de Vijver. Breast Cancer Res 2006
117
19

Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast.
Anne Vincent-Salomon, Carlo Lucchesi, Nadège Gruel, Virginie Raynal, Gaëlle Pierron, Rémi Goudefroye, Fabien Reyal, François Radvanyi, Rémy Salmon, Jean-Paul Thiery,[...]. Clin Cancer Res 2008
111
19

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.
C Correa, P McGale, C Taylor, Y Wang, M Clarke, C Davies, R Peto, N Bijker, L Solin, S Darby. J Natl Cancer Inst Monogr 2010
394
19


Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George. Lancet Oncol 2011
329
16

Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.
Mona L Gauthier, Hal K Berman, Caroline Miller, Krystyna Kozakeiwicz, Karen Chew, Dan Moore, Joseph Rabban, Yunn Yi Chen, Karla Kerlikowske, Thea D Tlsty. Cancer Cell 2007
170
16

Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.
Rulla M Tamimi, Heather J Baer, Jonathan Marotti, Mark Galan, Laurie Galaburda, Yineng Fu, Anne C Deitz, James L Connolly, Stuart J Schnitt, Graham A Colditz,[...]. Breast Cancer Res 2008
218
16

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006
16

Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler,[...]. Proc Natl Acad Sci U S A 2003
16

Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
K Han, S Nofech-Mozes, S Narod, W Hanna, D Vesprini, R Saskin, C Taylor, I Kong, L Paszat, E Rakovitch. Clin Oncol (R Coll Radiol) 2012
35
16



Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial.
A Ringberg, H Nordgren, S Thorstensson, I Idvall, H Garmo, B Granstrand, L G Arnesson, K Sandelin, A Wallgren, H Anderson,[...]. Eur J Cancer 2007
58
16

Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study.
Wenjing Zhou, Karin Jirström, Rose-Marie Amini, Marie-Louise Fjällskog, Thomas Sollie, Henrik Lindman, Therese Sørlie, Carl Blomqvist, Fredrik Wärnberg. BMC Cancer 2013
41
16

Molecular phenotypes of DCIS predict overall and invasive recurrence.
K E Williams, N L P Barnes, A Cramer, R Johnson, K Cheema, J Morris, M Howe, N J Bundred. Ann Oncol 2015
68
16

Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
F Wärnberg, H Nordgren, L Bergkvist, L Holmberg. Br J Cancer 2001
90
12

National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
Carmen J Allegra, Denise R Aberle, Pamela Ganschow, Stephen M Hahn, Clara N Lee, Sandra Millon-Underwood, Malcolm C Pike, Susan D Reed, Audrey F Saftlas, Susan A Scarvalone,[...]. J Natl Cancer Inst 2010
152
12

Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
Rodica Stackievicz, Haim Paran, Joelle Bernheim, Mayra Shapira, Neomy Weisenberg, Tzvi Kaufman, Ehud Klein, Mordechai Gutman. Isr Med Assoc J 2010
10
40

High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS.
S Roka, M Rudas, S Taucher, P Dubsky, T Bachleitner-Hofmann, D Kandioler, M Gnant, R Jakesz. Eur J Surg Oncol 2004
32
12

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
Maggie C U Cheang, David Voduc, Chris Bajdik, Samuel Leung, Steven McKinney, Stephen K Chia, Charles M Perou, Torsten O Nielsen. Clin Cancer Res 2008
844
12

Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
David J Dabbs, Mamatha Chivukula, Gloria Carter, Rohit Bhargava. Mod Pathol 2006
93
12

Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
D C Allred, J M Harvey, M Berardo, G M Clark. Mod Pathol 1998
12

Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes.
H Buerger, F Otterbach, R Simon, K L Schäfer, C Poremba, R Diallo, C Brinkschmidt, B Dockhorn-Dworniczak, W Boecker. J Pathol 1999
182
12

Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers.
Aye Aye Thike, Jabed Iqbal, Poh Yian Cheok, Angela Phek Yoon Chong, Gary Man-Kit Tse, Benita Tan, Patrick Tan, Nan Soon Wong, Puay Hoon Tan. Am J Surg Pathol 2010
71
12

Epidemiology of ductal carcinoma in situ.
Karla Kerlikowske. J Natl Cancer Inst Monogr 2010
127
12

Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy.
Karla Kerlikowske, Annette Molinaro, Imok Cha, Britt-Marie Ljung, Virginia L Ernster, Kim Stewart, Karen Chew, Dan H Moore, Fred Waldman. J Natl Cancer Inst 2003
175
12

Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes.
Beth A Virnig, Todd M Tuttle, Tatyana Shamliyan, Robert L Kane. J Natl Cancer Inst 2010
376
12


Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
D Craig Allred, Stewart J Anderson, Soonmyung Paik, D Lawrence Wickerham, Iris D Nagtegaal, Sandra M Swain, Elefetherios P Mamounas, Thomas B Julian, Charles E Geyer, Joseph P Costantino,[...]. J Clin Oncol 2012
197
12

Detection of ductal carcinoma in situ in women undergoing screening mammography.
Virginia L Ernster, Rachel Ballard-Barbash, William E Barlow, Yingye Zheng, Donald L Weaver, Gary Cutter, Bonnie C Yankaskas, Robert Rosenberg, Patricia A Carney, Karla Kerlikowske,[...]. J Natl Cancer Inst 2002
429
12

Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis.
Shi-Yi Wang, Tatyana Shamliyan, Beth A Virnig, Robert Kane. Breast Cancer Res Treat 2011
98
12

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.
Ning Liao, Guo-chun Zhang, Yan-hui Liu, Xue-rui Li, Meng Yao, Fang-ping Xu, Li Li, Yi-long Wu. Pathol Res Pract 2011
31
12

Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
J P Julien, N Bijker, I S Fentiman, J L Peterse, V Delledonne, P Rouanet, A Avril, R Sylvester, F Mignolet, H Bartelink,[...]. Lancet 2000
405
12


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.